The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial.
head and neck cancer
immunotherapy
locoregional treatment
nivolumab
squamous cell carcinoma
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
20 Apr 2020
20 Apr 2020
Historique:
received:
23
03
2020
revised:
12
04
2020
accepted:
18
04
2020
entrez:
25
4
2020
pubmed:
25
4
2020
medline:
25
4
2020
Statut:
epublish
Résumé
Previous locoregional treatment could affect the response to nivolumab in platinum-refractory recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The aim of this study is to evaluate the impact of the clinicopathological characteristics and previous treatment in predicting early progression to nivolumab in a real-world population. This is an observational, multicenter retrospective/prospective study including patients (pts) with platinum refractory R/M HNSCC who received nivolumab 240 mg every 2 weeks from October 2018 to October 2019. We analyzed the association between previous treatment, clinicopathological characteristics, and early progression (within 3 months). Data from 61 pts were reviewed. Median age was 67 years (30-82). Forty-two pts (69%) received previous locoregional treatment. Early progression to nivolumab occurred in 36 pts (59%), while clinical benefit (stable disease and partial response) was achieved in 25 pts (41%). Early progression to nivolumab was significantly associated to previous locoregional treatment both at univariate and multivariate analysis ( nivolumab in R/M HNSCC is burdened with a high early progression rate. Previous wide neck dissection and high dose radiotherapy may compromise the efficacy of nivolumab, distorting the anatomy of the local lymphatic system and hindering the priming of immune response.
Sections du résumé
BACKGROUND
BACKGROUND
Previous locoregional treatment could affect the response to nivolumab in platinum-refractory recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The aim of this study is to evaluate the impact of the clinicopathological characteristics and previous treatment in predicting early progression to nivolumab in a real-world population.
METHODS
METHODS
This is an observational, multicenter retrospective/prospective study including patients (pts) with platinum refractory R/M HNSCC who received nivolumab 240 mg every 2 weeks from October 2018 to October 2019. We analyzed the association between previous treatment, clinicopathological characteristics, and early progression (within 3 months).
RESULTS
RESULTS
Data from 61 pts were reviewed. Median age was 67 years (30-82). Forty-two pts (69%) received previous locoregional treatment. Early progression to nivolumab occurred in 36 pts (59%), while clinical benefit (stable disease and partial response) was achieved in 25 pts (41%). Early progression to nivolumab was significantly associated to previous locoregional treatment both at univariate and multivariate analysis (
CONCLUSION
CONCLUSIONS
nivolumab in R/M HNSCC is burdened with a high early progression rate. Previous wide neck dissection and high dose radiotherapy may compromise the efficacy of nivolumab, distorting the anatomy of the local lymphatic system and hindering the priming of immune response.
Identifiants
pubmed: 32326034
pii: vaccines8020191
doi: 10.3390/vaccines8020191
pmc: PMC7349768
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
J Thorac Oncol. 2017 Dec;12(12):1798-1805
pubmed: 28939128
Vaccine. 2015 Dec 16;33(51):7415-7422
pubmed: 26148880
J Radiat Oncol. 2015;4:339-345
pubmed: 26709361
N Engl J Med. 2008 Sep 11;359(11):1116-27
pubmed: 18784101
Nat Med. 2003 May;9(5):562-7
pubmed: 12704383
Acta Otolaryngol. 2019 Oct;139(10):918-925
pubmed: 31460818
Cancer Immunol Res. 2014 Sep;2(9):846-56
pubmed: 24872026
Lancet Oncol. 2017 Mar;18(3):e143-e152
pubmed: 28271869
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
J Immunother Cancer. 2018 Sep 3;6(1):86
pubmed: 30176921
Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467-75
pubmed: 15734974
Cancer Discov. 2016 Dec;6(12):1382-1399
pubmed: 27663893
Nat Rev Clin Oncol. 2017 Jun;14(6):365-379
pubmed: 28094262
Cancer Res. 2013 Jan 1;73(1):97-107
pubmed: 23090117
J Immunother. 2010 Oct;33(8):798-809
pubmed: 20842057
J Transl Med. 2019 Mar 27;17(1):99
pubmed: 30917841
Cell Immunol. 2015 Mar;294(1):54-9
pubmed: 25687508
Clin Cancer Res. 2016 Feb 15;22(4):886-94
pubmed: 26446948
Int Immunol. 2007 Oct;19(10):1223-34
pubmed: 17898045
Cancer Invest. 1999;17(1):56-72
pubmed: 10999050
Future Oncol. 2019 Mar;15(8):909-923
pubmed: 30669875
Oncotarget. 2017 Nov 1;8(59):99336-99346
pubmed: 29245905
Clin Exp Immunol. 2012 Sep;169(3):205-12
pubmed: 22861359
Cancer Res. 2005 Feb 1;65(3):1089-96
pubmed: 15705911
Trends Immunol. 2018 Aug;39(8):644-655
pubmed: 30001871
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Oncoimmunology. 2012 Oct 1;1(7):1084-1094
pubmed: 23170256
Ann Surg. 2009 May;249(5):727-34
pubmed: 19387333
Clin Cancer Res. 2014 Nov 1;20(21):5384-91
pubmed: 25204552
Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6681-8
pubmed: 17982122
JAMA Oncol. 2018 Mar 1;4(3):374-378
pubmed: 28975219
Mayo Clin Proc. 2016 Mar;91(3):386-96
pubmed: 26944243
Clinics (Sao Paulo). 2018 Dec 10;73(suppl 1):e557s
pubmed: 30540123